Newsfeeds - Spark Newswire

1 minute read

Fusion Pharma’s Stock Moves Higher As Radiopharmaceutical Candidate Shows Early Promising Action In Solid Tumor Study

Today, 4:45 PM

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) has announced preliminary Phase 1 data from the single-dose portion of the study evaluating FPI-1434 in patients…

AZN

2 minute read

22 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 4:45 PM

Gainers Unique Fabricating, Inc. (NASDAQ: UFAB) rose 43.1% to $4.68 in pre-market trading after the company announced the extension of its Forbearance Agreement with its Lenders through February 28, 2022.

ATXI

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 4:45 PM

Gainers

APLS

1 minute read

Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Single-Dose Portion Of Phase 1 Study Of FPI-1434 ; Says Candidate ‘demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity’

By Bill Haddad

Today, 4:45 PM

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across

FUSN

1 minute read

Uncategorized

Fusion Pharmaceuticals Q1 EPS $(0.42) Up From $(6.01) YoY

By Bill Haddad

Today, 4:45 PM

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.42) per share. This is a 93.01 percent increase over losses of $(6.01) per share from the same period last year.

FUSN

1 minute read

Uncategorized

Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study

By Vandana Singh

Today, 4:45 PM

Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion’s lead candidate, FPI-1434, in…

FUSN

Latest news

Fusion Pharma’s Stock Moves Higher As Radiopharmaceutical Candidate Shows Early Promising Action In Solid Tumor Study

22 Stocks Moving in Tuesday’s Pre-Market Session

12 Health Care Stocks Moving In Monday’s After-Market Session

Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Single-Dose Portion Of Phase 1 Study Of FPI-1434 ; Says Candidate ‘demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity’

Fusion Pharmaceuticals Q1 EPS $(0.42) Up From $(6.01) YoY

Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study